Knight Therapeutics IncKnight Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The Disclosure rating covers seventeen UN Sustainable Development Goals including: 'No Poverty', 'Responsible Production & Consumption' and 'Peace, Justice & Strong Institutions'. Full Sustainability assessment of Knight Therapeutics Inc are accessed by registering for free. The Sustainability assessment for Knight Therapeutics Inc represents the company's transparency towards the United Nations SDGs.

Knight Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.2; made up of an environmental score of 6.4, social score of 8.0 and governance score of 4.0.

SDG Transparency Score for Knight Therapeutics Inc 
Low
0 - 3

6.2

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Knight Therapeutics Inc 
6.4

Environmental

8.0

Social

4.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
563ReproCell Inc
6.3
High
563Venus Remedies Ltd
6.3
High
586Knight Therapeutics Inc
6.2
High
586Althea Group Holdings Ltd
6.2
High
586AlzeCure Pharma AB
6.2
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Knight Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Knight Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Knight Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Knight Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does Knight Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Knight Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Knight Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does Knight Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Knight Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Knight Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Knight Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Knight Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Knight Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Knight Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does Knight Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does Knight Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Knight Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Knight Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Sorry!

Failed to process!